alexa Systemic lupus erythematosus | Germany| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Relevant Topics

Systemic Lupus Erythematosus

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Systemic lupus erythematosus

     Disease pathophysiology: Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain, and other organs. There are many kinds of lupus. The most common type is systemic lupus erythematosus (SLE), which affects many internal organs in the body. SLE most often harms the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. The course of the disease is unpredictable, with periods of illness (called flares) alternating with remissions. General symptoms associated with lupus include low-grade fever, loss of appetite, nausea, muscle aches, joint pains, fatigue. 

  • Systemic lupus erythematosus

     Treatment: Treatment of Systemic lupus erythematosus includes anti-inflammatory medications for joint pain and stiffness, steroid creams for rashes, corticosteroids of varying doses to minimize the immune response, antimalarial drugs for skin and joint problems. During these periods, carefully prescribed exercise is still important to maintain muscle tone and range of motion in the joints. Major Research: Research is geared towards finding a possible cause, a cure, and more effective treatments for people with lupus. A study called BLISS-76 tested the drug, belimumab, and a fully human monoclonal anti-BAFF (or anti-BLyS) antibody. BAFF stimulates and extends the life of B lymphocytes, which produce antibodies against foreign and self-cells. It was approved by the FDA in March 2011.

  • Systemic lupus erythematosus

     Statistcs: One hundred and seventy eight discoid lupus erythematosus, were absorved in the years (1995-2006) and during routine control visits. Leukopenia (38%) and lymphopenia (52%) were observed more often in patients with systemic lupus erythematosus than reported previously. Photosensitivity characterized all groups, especially patients with subacute cutaneous lupus erythematosus (87%). 

Expert PPTs

Speaker PPTs


High Impact List of Articles

Conference Proceedings